openPR Logo
Press release

GCC Clinical Trial Market Outlook Insight 2025

08-24-2020 12:41 PM CET | Health & Medicine

Press release from: Kuick Resarch

"GCC Clinical Trial Market Outlook 2025" Report Highlights:

• GCC Clinical Trial Market Opportunity: >US$ 500 Million
• GCC Disease Prevalence & Statistics
• Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials
• Clinical Trials for Cancer in GCC: > 120 Trials
• Guidelines For Conducting Clinical Trials by Country
• Ongoing Clinical Trials Insight by Country

Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration

Table of Contents

1. GCC Clinical Market Regional Insights

2. GCC Clinical Trial Market Dynamics

2.1 Driving Forces for GCC Clinical Trial Market
2.2 Challenges for GCC Clinical Trial Market

3. GCC - Regulatory Aspects of Pharmaceuticals

3.1 Gulf Central Committee for Drug Registrations (GCC-DR)
3.2 Regulatory Review Process
3.3 Centralized Registration
3.4 Decentralized Drug Registration Regulation
3.4.1 Saudi Arabia
3.4.2 Kuwait
3.4.3 UAE
3.4.4 Bahrain
3.4.5 Qatar
3.4.6 Oman
3.5 Gulf Joint Procurement Program

4. GCC Disease Prevalence & Statistics

4.1 Cancer
4.1.1 Overview
4.1.2 Prevalence by Cancer Type & Gender
4.1.3 Cancer Prevalence & Statistics by GCC Countries
4.2 Diabetes
4.3 HIV/AIDS
4.4 Cardiovascular Diseases
4.4.1 Coronary Heart Disease
4.4.2 Hypertension
4.4.3 Stroke
4.5 Obesity
4.6 Respiratory Disorders
4.6.1 Asthma
4.6.2 Tuberculosis
4.6.3 Influenza & Pneumonia
4.6.4 Other Respiratory Diseases - COPD & Cystic Fibrosis
4.7 Alzheimer’s Disease/Dementia

5. Saudi Arabia - Ongoing Clinical Trials Insight

5.1 Overview
5.2 By Indication
5.2.1 Cancer
5.2.2 Diabetes
5.2.3 Cardiovascular Diseases
5.2.4 Respiratory Diseases Excluding Lung Cancer

6. Saudi Arabia - Guidelines For Conducting Clinical Trials

6.1 The Principles of SFDA Guidelines
6.2 Protection of Trial Subjects
6.3 Institutional Review Board (IRB) Committee
6.3.1 Responsibilities
6.3.2 Composition, Functions, and Operations
6.3.3 Procedures
6.3.4 Records
6.4 Investigators
6.4.1 Qualifications and Agreements
6.4.2 Adequate Resources & Medical Care of Trial Subjects
6.5 Clinical Trial Protocols


7. UAE - Ongoing Clinical Trials Insight

7.1 Overview
7.2 By Indication
7.2.1 Cancer
7.2.2 Diabetes
7.2.3 CVS Disorders

8. UAE - Guidelines For Clinical Trials Conduction

8.1 General Provisions For Clinical Trials
8.1.1 Purpose & Scope
8.1.2 Clinical Trials Background
8.2 Suitability Of Individuals AND Sites Involved In Conducting The Clinical Trial
8.3 Protection of Subjects & Informed Consent
8.3.1 Research Subjects
8.3.2 Information and Consent
8.4 Clinical Trials With Vulnerable Groups (Vulnerable Subjects) Of Patients
8.5 Ethics & Research Committees
8.6 Authorization to Conduct Clinical Trials & Application to Ethics Committee
8.7 Amendments & Suspensions In Clinical Trials
8.7.1 Amendments In Clinical Trials
8.7.2 Suspension Of The Clinical Trial

9. Bahrain - Ongoing Clinical Trials Insight
9.1 Overview
9.2 By Indication

10. Bahrain - Guidelines for Clinical Trials Application

10.1 Introduction
10.2 The Application Process
10.3 Phase II &III Clinical Trials: Decision Process
10.4 Guidelines Phase IV Clinical Trials

10.4.1 Application Process
10.4.2 DECISION PROCESS
10.5 Amendments

11. Oman - Ongoing Clinical Trials Insight

11.1 Overview
11.2 By Indication
11.2.1 Sickle Cell Disease
11.2.2 Cancer

12. Oman - Guidelines for Clinical Trial Conduction

12.1 Provision & Prerequisites for a Clinical Trial
12.2 Protection of Clinical Trial Participants
12.2.1 Research and Ethics Committee
12.2.2 Informed Consent of Trial Participants
12.2.3 Privacy and Confidentiality
12.3 Documents and Requirements for Clinical Studies and Trials
12.3.1 Documents Required to be Submitted to Central RERAC for Approval of
Clinical Trials
12.3.2 Documents Required During the Clinical Conduct of the Trial
12.3.3 Other Documents which are Required During the Clinical Conduct of the
Trial
12.3.4 The Required Documents by the End of the Trial

13. Kuwait - Ongoing Clinical Trials Insight

13.1 Overview
13.2 By Indication
13.2.1 Cancer Related Trials
13.2.2 Diabetes Related Trial


14. Qatar - Ongoing Clinical Trials Insight

14.1 Overview
14.2 By Indication
14.2.1 Cancer Related Trials
14.2.2 Diabetes Related Trial
14.2.3 CVS Disorders
14.2.4 Respiratory Disease

15. Future Insights for GCC Clinical Trial Market

16. Competitive Landscape

16.1 Regional CROs
16.1.1 Innova
16.1.2 Antaea
16.1.3 ClinServ International
16.1.4 MCRO
16.1.5 KAU MED Clinical Research Organization
16.1.6 RAY CRO
16.1.7 MCT CRO
16.1.8 ClinArt MENA
16.1.9 Pharmaceutical Development Company
16.1.10 Nagy Research MEACRO
16.2 Multinational CROs
16.2.1 Quotient Sciences
16.2.2 MedPace
16.2.3 Europe, Middle East & Africa Clinical Research (EMEACR)
16.2.4 Pharmaceutical Product Development (PPD)
16.2.5 MedPace
16.2.6 PRA Health Sciences
16.2.7 KCR
16.2.8 ICON
16.2.9 Covance
16.2.10 Parexel

Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-09810410366

Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GCC Clinical Trial Market Outlook Insight 2025 here

News-ID: 2119743 • Views: 229

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
Saudi Arabia Diabetes Drug Device Market To Surpass US$ 2.5 Billion By 2025
"Saudi Arabia Diabetes Drug & Insulin Delivery Device Market Opportunity Outlook 2025" Report highlight: • Diabetes Drug Market Opportunity: > US$ 1.5 Billion by 2025 • Diabetes Device Market Opportunity: > US$ 1 Billion by 2025 • Glucose Monitoring Device Market Absolute Growth: 33% (2019-2025) • Oral Hypoglycemic Drugs Market - Availability, Dosage & Price Analysis • Insulin Availability, Dosage & Price Analysis • Insulin Delivery Device Market - Availability, Price & Sales Analysis • Glucose Monitoring Device Market - Availability & Price

All 5 Releases


More Releases for Trial

Clinical Trial Management System
According to a new market report published by Persistence Market Research “Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019” the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. Request Report TOC @ https://www.persistencemarketresearch.com/methodology/3017
Global Clinical Trial Imaging Market
Global Clinical Trial Imaging Market is expected to reach USD 1297.39 Million by 2024 from USD 773.2 Million in 2016 at CAGR of 6.68% (Detailed analysis of the market CAGR is provided in the report). Global Clinical Trial Imaging Market is segmented by product & services, imaging modality, end user, and geography. Imaging Modality segment is classified as magnetic resonance imaging, computed tomography, positron emission tomography, ultrasound and others. Computed Tomography
Paediatric Clinical Trial Conference - When designing a Paediatric clinical tria …
Press Release – 12.02.2018 When designing a Paediatric clinical trial, a paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral
Global Dysthymia Clinical Trial Market
The Dysthymia Clinical Trial Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Dysthymia is often characterized by chronic depression. Symptoms of dysthymia are the same as for depression and usually not as severe as major depression. Key symptom of dysthymia is daily
Thompson & Knight Expands Trial Practice
Dallas (August 15, 2011) – The global law firm of Thompson & Knight LLP is pleased to announce that Nathan H. Aduddell* has joined the Firm’s Trial Department as an Associate in the Dallas office. “Nathan comes to us with an excellent record of scholastic achievement and success in trial-related competitions, all accomplishments we believe will enhance his trial skills. We are very pleased to have him join
Clinical Trial Logistics
Clinical Trial Logistics 16th to 17th May 2011, Marriott Regents Park, London, United Kingdom. It currently costs just over £500 million ($800 million) to bring a new chemical to market and development timelines continue to fall in the 10-15 year range. A key reason for high R&D costs is due to logistical failures including failure to recruit patients on time. A way to avoid this is to move clinical trials